anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A bio-information presenting method and a bio-information presenting device, for presenting the bio-information, indicating the movement of a physical organ of a user, for the user, are disclosed. The movement of a bodily organ of the user, controlled voluntarily or involuntarily, is fed back to the user. A background image is stored in a storage unit for image data for composition 5. An image processing unit 6 compounds an image of the user, captured by a camera 8, with a background image. In compounding the images, the image of the user is subjected to fade-in and fade-out in association with an output of a breathing sensor 7. The user is apprized of the inhalation period, exhalation period and the depth of breathing, based on an image demonstrated on a display unit 10. The change in the display image surface produces certain changes in the user&#39;s breathing. The display unit 10 of the breathing visualizing device 1 is changed responsive to the breathing of the user. A feedback loop is formed in this manner between the breathing visualizing device 1 and the respiratory organ of the user.
PURPOSE:To obtain a dental filling composition, good in operating efficiency of a paste, transparency and mechanical strength of a hardened product, excellent in gloss and smoothness of the surface of the hardened product and having a low water absorption factor. CONSTITUTION:The objective dental filling composition is composed of an inorganic filler and a polymerizable monomer. In this composition, the inorganic filler is a spherical inorganic oxide mixture of spherical inorganic oxides (e.g. spherical silica synthesized by hydrolysis and polymerization of an alkoxysilane), having a particle diameter within the range of 0.01-30mum and composed of at least two groups having different average particle diameters. The spherical inorganic oxide having an average particle diameter within the range of 1-30mum is contained as one of the groups and the ratio of the average particle diameters in the two groups having the mutually approximate average particle diameters is &gt;=2. The group having a larger average particle diameter occupies &gt;=50% based on the total weight of the two groups.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a deodorizing agent composition for pet having deodorizing effect on the odor of highly odorous animals such as dog to not only develop the effect immediately after the application but also continue the effect to the odor generating after the application.  &lt;P&gt;SOLUTION: The deodorizing agent composition for pet contains one or more kinds of oils selected from sunflower oil, macadamia nut oil, avocado oil, sesame oil and coconut oil. The content of the oil in the composition is preferably 0.005-3 wt.%. The composition of the invention preferably further contains a surfactant in an amount of 0.05-10 wt.%. The surfactant is preferably a fatty acid ester-type nonionic surfactant, a polyoxyalkylene-type nonionic surfactant, an alkylalkanolamide-type nonionic surfactant or an alkylglucoside-type nonionic surfactant.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Medical foods that create fertility enhancement also improve the health of a fetus or child. Multiple examples demonstrate this in mammals. To maximize this effect, the mother continues to consume the medical food into the gestation period. Both mother and fetus benefit from higher immunity and lower cortisol. Superior colostrum further builds the child&#39;s immune system. Good health as an infant foreshadows health advantages in later life.
Procedure for preparing vasoactive agents derived from benzofenone. It consists in the preparation of hexahidroxi - 2,3,4,3 &#34;, 4&#34;, 5 &#34;- benzophenone by condensation of pirogalol and galician acid. This reaction is performed preferably in the presence of catalysts such as anhydrous aluminum chloride, zinc anhydro chloride only or with phosphorox oxylloride, and boro trifluoride in a solvent like dioxane. The reaction is effected preferably at temperatures comprised between 100 and 120 degrees. &gt; application in the preparation of pharmaceutical compounds used in the treatment of functional deficits and metabolic disturbances resulting from a cerebral and peripheral circulatory insufficiency. (Machine-translation by Google Translate, not legally binding)
Apparatus (10) is provided including an input device, a medical risk database (14), a data processor (16), and a communication device (12). Data entered in the input device, usually by a health care professional, defines a patient data record (22). The medical risk database (14) associates certain patient data entered into the data record (22), which increases the risk of a missed medical care opportunity, with additional medical care to address the risk. The communication device (12) responds to the identification of patient data presenting a medical risk by communicating to a health care professional additional medical care selected to identify and take advantage of a medical care opportunity. Templates are also disclosed having &#39;red light green light&#39; indicators that indicate red to prompt consideration of a system and green to indicate it has been considered. A triage template and key information to provide additional information to the diagnosing or treating professional are also provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an anti-periodontal disease medicine which inhibits the activity of a trypsin-like protease produced by Porphyromonas gingivalis, further inhibits the activities of the trypsin-like protease and a collagenase produced by the bacterium, and can effectively prevent and treat the periodontal disease.  &lt;P&gt;SOLUTION: This anti-periodontal disease medicine contains an extract which is obtained by extracting one or more galenicals selected from the group consisting of Apocynum venetum L., the stamens of Nelumbunucifera Gaertn., and Coleus scutellarioides (L.) Benth. and has an action for inhibiting the activity of a trypsin-like protease produced by Porphyromonas gingivali, as an active ingredient. The anti-periodontal disease medicine contains an extract which is obtained by extracting one or more galenicals selected from the group consisting of Apocynum venetum L., the stamens of Nelumbunucifera Gaertn., and Coleus scutellarioides (L.) Benth. and has an action for inhibiting the activities of the trypsin-like protease and a collagenase produced by the Porphyromonas gingivali, as an active ingredient.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a dental hypesthesic agent easily performing continuous hypesthesia.  &lt;P&gt;SOLUTION: This hypesthetic agent is a composition containing an acid and organic polymer. The organic polymer contains carboxyl and/or hydroxy group and provides an especially suitable composition for the hypesthesia of tooth. In one of executing forms, the composition contains an acid having 0.5-20 wt. % solubility in water or a mixture of 50 wt. % water and 50 wt. % ethanol. In one of executing forms, the composition contains the acid having a protein-precipitating characteristic and/or calcium-precipitating characteristic. In one embodiment, the composition contains a carboxylic acid, sulfonic acid and/or phosphonic acid as the acid.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE: To obtain a cosmetic base capable of imparting luster and moistness to hair or skin when touched with a hair or a skin cosmetic, improving the combing properties of hair, preventing the hair from splitting and further smoothing the skin. CONSTITUTION: This cosmetic base comprises a silylated peptide having a functional group containing only one silicon atom, e.g. a group of formula I [R&lt;1&gt; to R&lt;3&gt; are each methyl or OH; (a) is 1-3] covalently bound to amino group in a peptide containing the amino group in the side chain of an amino acid. The silylated peptide is obtained by reacting peptides with, e.g. a silyl compound of formula II (R&lt;6&gt; to R&lt;8&gt; are each methyl, methoxy, ethoxy, OH or a halogen; X is a halogen). A compound of formula III [R&lt;4&gt; is a residue after removing terminal amino group of a basic amino acid having the amino group at the terminal of side chain; R&lt;5&gt; is amino group other than R&lt;4&gt; ; (m) and (n) are each 0-200; (m+n) is 1-200] is cited as the representative silylated peptide.
&lt;P&gt;PROBLEM TO BE SOLVED: To allow mixed substances to function when used by a user by mixing the functional substances inside a base.  &lt;P&gt;SOLUTION: A tattoo sticker is obtained as follows. The functional substances 3 are mixed inside the base 2, and various patterns are formed on the upper surface. Adhesion parts 4 adherable onto skin are formed in a plurality of places of a peripheral edge part on the lower surface of the base 2. Release sheets 5 are temporarily fitted to the base 2 at the side opposite from the adhesion parts 4.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
A preparation for oral administration in the form of a tablet or capsule e.g. gelatin capsule, for the treatment of trichomonas vaginalis vaginitis, contains 2-acylamino-5-nitrothiazole of formula: &lt;FORM:0759274/VI/1&gt; R being an acyl group preferably having up to 10 carbon atoms or being a lauroyl radical e.g. acetyl, propionyl, butyryl, iso-butyryl, caproyl, in intimate admixture with an inert solid diluent e.g. binders, lubricants, and preferably alkaline materials.  The preparation is mixed in a moist condition, granulated, compressed into tablet form and may be coated in gelatin before covering with an enteric coating such as acid-insoluble, alkali-soluble ion exchange resins, high melting fats and waxes e.g. carnauba and beeswax, lipid materials e.g. glyceryl esters of fatty acids, esters of polyhydric compounds e.g. long chain fatty acid partial esters and their oxyalkylene derivatives of hexital anhydrides; resins e.g. gum-mastic, shellac, rosin; fat soluble compounds e.g. abietic acid, bile acids and cholestrol; cellulose derivatives e.g. cellulose nitrate, acetate, phthalate, acetatephthalate; and non-toxic, water-soluble salts of polyvinyl phthalates and phenyl salicylates.  Examples of inert diluents are lactose, dextrose, sucrose, sodium chloride, glycine, kaolin and starch.  Examples of binders are acacia, zein, tragacanth, gelatin, sodium carboxymethyl-cellulose and methyl cellulose.  Examples of lubricants are mineral oils, stearic acid, magnesium and zinc stearate, stearyl alcohol and mono- or poly-glycol esters. Satisfactory alkaline materials are aluminium hydroxide, disodium phosphate, dipotassium phosphate, sodium carbonate and bicarbonate, and alkaline or alkaline earth metal salts of glycine.
In the present invention, there is disclosed an indole derivative or a salt thereof, or a solvate thereof, pharmaceutical compositions in which the derivative is comprised as well as the use of this compound or composition in medicine. Particular indole compounds are selective for mammalian osteoclasts, acting to selectively inhibit their bone resorbing activity. These compounds are therefore considered to be particularly useful for the treatment and/or prophylaxis of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget&#39;s disease, hyperparathyroidism and related diseases. These compounds are also considered to possess antitumor activity, antiviral activity, antiulcer activity, immunosuppressant activity, antilipidemic activity, antiatherosclerotic activity and to be useful for the treatment of AIDS and Alzheimer&#39;s disease. Furthermore, these compounds are also considered useful in inhibiting angiogenesis i.e. the formation of new blood vessels, which is observed in various types of pathological conditions, such as rheumatoid arthritis, diabetic retinopathy, psoriasis and solid tumors.
(1) Leukoregulin (I) in pure form and its biological sub-units are new. It regulates the physiology and growth of malignant tumour cells without affecting the growth of normal cells. (I) directly lyses tumour cells; it suppresses tumour cell proliferation; it enhances the susceptibility of tumour cells to NK cell mediated lysis; it alters tumour cell surface conformation and permeability; and it inhibits the carcinogenic transformation of normal cells. (2) Isolated concd. human (I) having a molecular wt. of 120,000-140,000 and isoelectric focussing points at pH 4.8-5.5 and 7.5-8.3 is new. It is eluted on anion exchange chromatography at 0.07-0.12 M NaCl salt conc. It is partly digested by protease but not by neuraminidase and it produces subunits on dissociation of mol. wt. 30,000-35,000. (3) Biologically active compsn. comprising an effective amt. of (I) is new. (4) Cell producing human (I) and consisting of transformed B cells or hybridoma cells is new. It is obtd. from the peripheral blood of a cancer patient who has been inoculated with a vaccine comprising viable cells from the patient&#39;s own tumour, or a culture of the cells. (5) Cells producing human (I) transformed by a transfer vector contg. the gene for (I), or a biologically subunit of it, is new. (6) Monoclonal antibody specific for (I) cell surface receptor is new. (7) Hybridoma producing the monoclonal antibody defined above is new. (8) (I) or its subunit is used in a method for treating tumour cells in tissue, the method comprising the ex-vivo exposure of tumour cells. Esp. viable bone marrow cells for use in reconstituting a patient&#39;s bone marrow are first exposed to (I) or its subunit.
&lt;P&gt;PROBLEM TO BE SOLVED: To produce a soap with a very high viscosity like a rice cake.  &lt;P&gt;SOLUTION: A solid raw material soap comprises 5% or more of glycerine, 10% or more of propylene glycol, 10% or more of sodium stearate, 5% or more of sodium laurate, 5% or more of sodium polyoxyethylene lauryl ether sulfate, 0.5% or more of lauryl sulfate, and 25% or more of water, by weight. A solid salt comprises 2% or more of sodium chloride, 20% or more of potassium chloride, and 20% or more of magnesium chloride, by weight. The solid salt is dissolved in water to prepare a saturated solution of the salt. The raw material soap is heated to a temperature equal to the melting point thereof or higher to melt it. The saturated solution of the salt is mixed with the melted raw material soap, in a ratio by weight of the saturated solution to the raw material soap of 3-11 to 100, followed by cooling the mixture to room temperature.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The certified doctor in United States, use pentobabital sodium as the hypnotic to refrain central nervous system. Pentobabital sodium can be patience to the body after two weeks, and the effect decrease half, and have lingering effects and remain effects. The making method and pharmacological activity about the six kinds of plants and sodium pentobarbital&#39;s synergistic action wares are gaven patent. Under the cautious and strict conditions, extract the plant ingredients, absorb them by WLD resin, separate and purify them, and use the finger mark atlas quantity to make sure that the end product poise and stabilize. Six plant compound wares have sedate, hypnotize and synergy pentobabital sodium, anti-penfourzopol. The clinical use proved the reliability. It is safe and compensatory to the pentobabital sodium. It solves the hypnotic&#39;s tolerance and addiction. It solves the problem, which is expected to conquer for a long time.
FIELD: chemistry, medicine, cosmetology, pharmacology. SUBSTANCE: invention proposes new compositions or combinations of the known compositions based on Amarory&#39;s reaction of the formula R 1 -NH-R 2  where R 1  means D-form of 1-amino-1-deoxy-2-ketose radical, derivative of saccharide radical taken among the following group: glucose, galactose, rhamnose, fructose, mannose, 6-deoxyglucose and glycoseamine or oligo- and polysaccharides; R 2  means L-form of amino acid or peptide radical as an active component of pharmaceutical preparations showing ability to produce interferons and other cytokines. Cosmetic compositions prepared on the basis of the above indicated compositions are used for cellular nutrition, tissue regeneration and/or immunomodulation. Invention proposes also a method of preparing the mixture of immunotropic compounds based on Amadory&#39;s rearrangement. EFFECT: broadened arsenal of agents. 14 cl, 4 tbl, 6 dwg, 13 ex
PURPOSE:To obtain an impression material having improved moisture resistance and insensitive to moisture in atmosphere, by adding an additive such as a hydrocarbon having specific carbon number, a silane coupling agent, etc. to an impression material composed mainly of an alginic acid salt. CONSTITUTION:(A) An algenic acid salt is compounded with (B) a curing agent consisting of calcium sulfate and/or lead silicate, (C) a filler such as diatomaceous earth, talc, silica, etc., and (D) an additive selected from (i) a &gt;=8C hydrocarbon, (ii) a silane coupling agent, (iii) a titanate coupling agent and (iv) a hydrophobic polymer having a contact angle of &gt;=45 deg., preferably &gt;=80 deg. (e.g., PE, PP, PVC, nylon, etc.). The amount of the additive is preferably 0.01-5.0wt%, especially 0.05-1.0wt% based on the impression material. The effect is especially remarkable when a phosphoric acid salt or an oxalic acid salt is added to the composition for the control of the gelation time within a proper range (e.g. 1- 5min) to improve the workability.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a health care supporting system which is efficient for patients and physicians as a result of the system enabling the physician at a remote site to view the patient&#39;s biological information and to give advice.  &lt;P&gt;SOLUTION: A terminal device 2 for patients transfers the patient&#39;s biological information to a database server device 3 through a communication network 4, and a formatted message producing means 18 automatically makes a formatted message, based on the biological information at the database server device 3. The physician edits the message based on the formatted message by a message editing means 7 at a terminal device 1 for physicians, and the edited message is housed in the database server device 3. The patient views the message from the physician on a display means 12 of the terminal device 2 for patients. Therefore, since the physician makes the message by the editing work to modify a part of the automatically produced formed message, he/she increases the work efficiency.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
PURPOSE:To industrially obtain the subject compound of high quality useful in the medical field without any loss in raw materials by feeding a solution of a lipid having the ability to form liposome films in an organic solvent into a tubular heater at a prescribed rate, heating and evaporating the solvent, etc. CONSTITUTION:A solution of a lipid having the ability to form liposome films in an organic solvent (e.g. pentane or hexane) in a raw material tank 1 is fed into a tubular heater 2 normally at a prescribed rate of about 1-100l/hr and heated therein to evaporate the organic solvent and provide a mixture of substantially a solid substance with vapor of the solvent. The resultant mixture is then introduced into a vacuum changer 3 under &lt;=300mmHg at a high speed to instantaneously volatilize the organic solvent and dry the solid substance, which is then recovered in a powder recovery device 6. Thereby, the objective powder for preparing the liposome is obtained. The lipid powder excellent in hydrating power is obtained by the afore-mentioned method.
PURPOSE:To provide new compounds useful as an intermediate for synthesis of an antineoplastic antibiotic M/43-37 F11. CONSTITUTION:Compounds of formula I (R&lt;1&gt; is a lower alkyl or an electron attracting substituent is an electron attractive substituent group; X is a halogen). The above-mentioned compounds can be obtained by introducing an electron attractive group into the hydroxyl group of a compound of formula II (R&lt;3&gt; is H, an electron attractive group or a lower alkyl) and then reacting a halogenation agent therewith in a radical condition. Introduction of the electron attractive group is carried out by adding and reacting an acylation agent (e.g. acetic acid anhydride) or a sulfonation agent (e.g. p-toluenesulfonic acid chloride) therewith. As the radical condition, addition of a radical initiator (e.g. azobisisobutylo-nitrile) or irradiation of light is used. In addition, an antibiotic M-143-37 F11 is obtained by treating the compound of formula I with a Lewis acid or hydrolyzing it in an acidic condition, then reacting formula R&lt;6&gt;-COOY (R&lt;6&gt; is H or a lower alkyl; Y is H, an alkaline metal or an organic base) therewith and subsequently hydrolyzing the resultant compound.
PROBLEM TO BE SOLVED: To obtain the subject first agent capable of providing easiness of washing away compatible with goodness in finger combing without squeaking of hair and excellent in correction of curly hair by including a specific polymer and a silicone oil in an aqueous solution containing a reducing agent and an alkaline agent. SOLUTION: This first agent is obtained by including (C) an alkyl-modified carboxyvinyl polymer and (D) a silicone oil (e.g. dimethylpolysiloxane) in an aqueous solution containing (A) a reducing agent (e.g. thioglycolic acid) and (B) an alkaline agent (e.g. aqueous ammonia). An acrylic acid-alkyl methacrylate copolymer having a structural unit represented by the formula CH2 -CHOOR1 - CH2 -CHCOOH-CH2 -CHCOOR2 (R1 and R2 are each a 10-30C alkyl) is preferred as the ingredient C. The amounts of the formulated ingredients in the first agent are preferably &lt;=20 wt.% ingredient A, &lt;=10 wt.% ingredient B, 0.05-5 wt.% ingredient C and 0.5-20 wt.% ingredient D.
Computer system (100) and method for index creation in a streaming database (130) with medical state parameters of different types associated with a plurality of patients (10) is provided to allow near-real-time access to medical state parameters reflecting medical states of patients. A message broker (110) receives messages in one or more incoming data streams (30). The messages include records with current measured medical state parameter values (11-1) of patients. A stream processor (120) processes incoming messages with a plurality of parameter augmentation algorithms (PAA1 to PAAn) wherein each parameter augmentation algorithm is adapted to derive additional computed medical state parameter values for the respective patient. Records with the computed values are then inserted via generated messages (mg&lt;sup&gt;∗&lt;/sup&gt;) into any incoming data stream. A data handler (140) can create persisted patient-signal specific stream data tables for yet unknown combinations of patient identifier and signal identifier in the streaming database (130), and can further create a block range index for the time information of said persisted stream data table. Records contained in the received and generated messages (m&lt;sup&gt;∗&lt;/sup&gt;, mg&lt;sup&gt;∗&lt;/sup&gt;) are then written into respective persisted patient-signal specific stream data tables (SDT-P2-S1 to SDT-P2-Sn) of the streaming database (130), and the respective block range indexes are updated accordingly upon record insertion.
FIELD: cosmetology, particularly, production of cosmetic agents for skin care. SUBSTANCE: composition contains the following ingredients in ratio, mas.%: ram lysed sperm, 43.0-45.0; hydrolyzed goat milk, 43.0-45.0; dimethylsulfoxide, 4.9-5.8; germall-plus, 0.1-0.2; distilled water, the balance. The ready product is frozen or lyophilized mass with storage life of 2 years. Composition is used for production of hygienic agents for skin care designed for mobilization of local humoral immunologic protective mechanisms supporting and restoring physiological full value of man&#39;s dermal integument. EFFECT: broadened assortment of cosmetic agents for skin care. 2 cl, 1 tbl